Patrys (ASX:PAB) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the quarter ended 30 September 2021.
Key highlights from this period include:
- Studies confirm full-sized IgG deoxymab antibody, PAT-DX3 is able to cross the blood brain barrier in animal model of primary brain cancer
- PAT-DX1 significantly improves survival in animal model of pancreatic cancer
- Preclinical data highlights the potential for using PAT-DX3 as a targeting agent in antibody drug conjugates (ADCs)
Our Company had a cash and short-term investment balance of A$9.8M at 30 September 2021.